Volition signs first commercial project utilizing rapid high-throughput model in the study of netosis

Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies  henderson, nev. , feb. 6, 2025 /prnewswire/ -- volitionrx limited (nyse american: vnrx) volition a multi-national epigenetics company, announces its first commercial sale of volition's high throughput synthetic sepsis method that measures neutrophil extracellular traps "nets" activation and inhibition in whole blood in real time, helping companies develop new therapeutics to combat sepsis and other nets-related disease.
VNRX Ratings Summary
VNRX Quant Ranking